Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
about
CixutumumabTargeting the insulin-like growth factor pathway in hepatocellular carcinomaActivation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotiniA selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitorsInhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachA moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesisDual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells.Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells.Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancerAnti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line.Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy.The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.Insulin-like growth factor: current concepts and new developments in cancer therapy.Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention.Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.IGF-1R as an anti-cancer target--trials and tribulationsTargeting insulin-like growth factor type 1 receptor in cancer therapy.Defining new paradigms for the treatment of pancreatic cancer.In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.Mechanisms of resistance to ErbB-targeted cancer therapeutics.Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines.Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells.IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
P2860
Q24609058-C25DB7D1-1564-4015-BEDD-9F59DD09466FQ27006846-F524268E-AA9E-4149-98F6-29C785498ED2Q30424348-42B34B34-15C1-4B26-B52D-52381FB805C2Q33275887-3EF93A7E-19C5-45B5-9C5A-8B709E3955A6Q33416585-D9333DF8-F8E3-4FB4-AD20-F7E78337FC24Q33627135-5EECC48F-C077-400F-B0F5-AA1A814C12E2Q33925323-D475ADD0-B236-4148-A55C-1C1EA83B790EQ34002933-B0502569-E8C3-4500-B0F0-5A82BC715CE2Q34442002-F09D0E52-D917-4C97-9E49-3522F05C6D5CQ34465028-65E49B0B-70D1-4C62-9F81-81BCEF833ADCQ34569071-F808729D-F49E-4202-9939-6E1EF97CF80EQ34777457-3B93C307-6643-4D37-9474-96635B93FF0FQ35094456-F8ADA4A3-8EC1-4EF7-B143-A0684C3A5D3AQ35102025-FFCA919B-C54D-44CB-BF9B-F513130B3C82Q35982635-151BA12E-5CF4-4E14-9C45-20644A9EC6A4Q36101895-E1958EA7-DE89-4751-9FA2-13A1E1F97BDAQ36230865-77DBB0D7-D029-4599-B481-239576CD8F79Q36393289-97D183AE-757A-4558-A77E-E9A58A8AFB16Q36499234-41551431-C028-43F9-B624-59F17140505CQ36731417-167D2906-6148-4D45-8FA9-7AE05D573030Q36955067-638C22BC-E791-438B-939A-01091EFD003EQ37047067-2A33CCD5-190F-4591-898E-7EC37F2F4FA3Q37321835-8A5CA459-DE40-4FEF-951C-508C6FA7CFD8Q37335142-08E89A2B-6660-4B82-8DA8-5C5910035FEDQ37353958-106D62B9-F1E5-4023-A8D9-D5212890BE66Q37624476-38EDA240-C5A4-4D79-A4DD-5BB5324FAF5EQ37860976-22513062-6F2C-410E-B7DD-BD5C717DDD63Q38850952-9679BD5C-A71E-4A85-8358-AB73C6D45F43Q39242812-83DDDE83-EFFE-4899-BB21-61AB707799CFQ39365739-8D660EFA-EFFC-4389-8A79-68C69E4D7188Q39865743-EA613E49-38D8-4B39-9B44-5E7AE91E57EBQ39971767-098BD386-CB8E-4847-8A65-47C38128733EQ41960486-EB845493-4442-4008-BB42-5188F8B707B5Q42107855-6D997C59-0B90-4A18-A96C-F49988FDA2D8Q42693300-1846C4A4-D5CF-4C1A-8AF1-4E98006A3401Q47105720-1E7EEF25-14E5-4B35-B3A9-A0FCC7A228BA
P2860
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@ast
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@en
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@nl
type
label
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@ast
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@en
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@nl
prefLabel
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@ast
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@en
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@nl
P2093
P2860
P356
P1476
Inhibition of insulin-like gro ...... ) in human breast cancer cells
@en
P2093
Anne Camirand
Mahvash Zakikhani
Michael Pollak
P2860
P2888
P304
P356
10.1186/BCR1028
P407
P577
2005-04-12T00:00:00Z
P5875
P6179
1018289267